Glutaric acidemia type II patient with thalassemia minor and novel electron transfer flavoprotein-A gene mutations: A case report and review of literature

Neslihan Yildirim Saral, Fehime Benli Aksungar, Cigdem Aktuglu-Zeybek, Julide Coskun, Ozlem Demirelce, Mustafa Serteser

Abstract
Glutaric acidemia type II (GA II), also known as multiple acyl-CoA dehydrogenase deficiency, is an autosomal recessive inborn error of amino acid and fatty acid metabolism. We report a case of GA II with novel electron transfer flavoprotein (ETF)-A mutations in a 2-year-old female with thalassemia minor. The patient developed an episode of hypoglycemia and hypotonicity...
on the postnatal first day. Laboratory investigations revealed elevations of multiple acyl carnitines indicating glutaric acidemia type II in newborn screening analysis. Urinary organic acids were evaluated for the confirmation and revealed a high glutaric acid excretion. Genetic analysis revealed two novel mutations in the ETF-A gene, which are considered to be compound heterozygote. At the 8 mo of life ketone therapy was added, which significantly increased the neuromotor development. The patient had been closely followed for two years with carnitine, riboflavin, coenzyme Q10, and ketone supplementation in addition to a high carbohydrate diet. Although the patient had comorbidity like thalassemia minor, her neuromotor development was normal for her age and had no major health problems. This specific case expands the previously reported spectrum of this disease.

Key words: Electron transfer flavoprotein-A mutation; Newborn screening; Glutaric acidemia type II; Inborn error of metabolism; Ketone bodies; Case report

© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Multiple acyl-CoA dehydrogenase deficiency (GA II) is an autosomal recessive inborn error of amino acid and fatty acid metabolism. We report a case of GA II with novel electron transfer flavoprotein (ETF)-A mutations in a 2-year-old female with thalassemia minor. Genetic analysis revealed two novel mutations in the ETF-A gene, which are considered to be the etiology for the disease. Most neonatal-onset patients of GA II may not survive due to progressive deterioration despite aggressive treatment. However, at 8 mo of age our patient, with the experimentally added ketone therapy, had no major health problems, and neuromotor development was normal for her age. The present case report is the only one reporting a patient with both GA II and thalassemia minor.

Saral NY, Aksunag FB, Aktuglu-Zeybek C, Coskun I, Demirelce O, Serteser M. Glutaric acidemia type II patient with thalassemia minor and novel electron transfer flavoprotein-A gene mutations: A case report and review of literature. World J Clin Cases 2018; 6(14): 786-790 Available from: URL: http://www.wjgnet.com/2307-8960/full/v6/i14/786.htm DOI: http://dx.doi.org/10.12998/wjcc.v6.i14.786

INTRODUCTION

Glutaric acidemia type II (GA II), also known as multiple acyl-CoA dehydrogenase deficiency, is an autosomal recessive inborn error of amino acid and fatty acid metabolism[1]. GA II is caused by a defect in the electron transfer flavoprotein (ETF) or ETF dehydrogenase (ETFDH) resulting in deficiencies in multiple acyl-CoA dehydrogenases[2]. The ETF/ETFDH deficiencies are responsible for multiple defects of the dehydrogenation system because they block not only fatty acid oxidation, but also the oxidation of branched-chain amino acids and of glutaryl-CoA on the catabolic pathway of lysine, hydroxylysine, and tryptophan[3].

There are three clinical phenotypes in GA II: neonatal form with congenital anomalies (most commonly cystic or dysplastic kidneys)[1]; neonatal form without congenital anomalies; and late onset form with myopathic phenotype and rarely metabolic acidosis[4]. All forms of GA II can be caused by defects in the genes encoding the ETF α and β subunits (ETF-A and ETF-B, respectively) or in the gene encoding ETF-QO (ETFDH). The majority of patients with ETF deficiency are found to have mutations in the ETF-A gene[1].

Neonatal onset form is usually fatal and characterized by severe non-ketotic hypoglycemia, metabolic acidosis, excretion of large amounts of fatty acid, and amino acid-derived metabolites with congenital anomalies[5]. In addition to hypoglycemia and metabolic acidosis, routine laboratory findings may include hyperammonemia and elevated liver transaminases. Cardiomyopathy may be present in some cases. Pathologic abnormalities include fatty infiltration of the liver, heart, and kidneys[1].

Treatment consists of a diet low in protein and fat together with carnitine, ubiquinone, and riboflavin supplementation. However, most neonatal-onset patients may not survive due to progressive deterioration despite aggressive treatment[1]. We hereby present a case of GA II, a neonatal form without congenital anomalies with a novel ETF-A mutation in a 2-year-old female with thalassemia minor.

CASE REPORT

The patient was born at full-term to nonconsanguineous parents after an uneventful pregnancy as the first child of the family with no history of metabolic diseases. The birth weight was 3192 g and height was 50 cm. Initial physical examination revealed a healthy infant with no dysmorphic features. An episode of hypoglycemia and hypotonia occurred on the postnatal first day, and the infant was admitted to the neonatal intensive care unit. Initial laboratory results revealed significant hypoglycemia with elevated transaminase levels.

An expanded newborn screening (NBS) sample obtained in the first week was reported to be positive for glutaric acidemia type II with elevations of multiple acylcarnitines. In particular, C4 butyrylcarnitine levels were extremely high, accompanied by elevated C5, C6, C8, C10, C14, and C5-DC glutaryl carnitine levels. Second-tier testing was carried out for NBS and urinary organic acids were evaluated for confirmation. Glutaric acid excretion was extremely high with increased levels of lactic acid, adipic acid, 5-hydroxyhexanoic acid, 2-hydroxy glutaric acid, and suberic acid. Radio logical examinations revealed normal cranial Doppler
ultrasonography (USG) and normal cranial magnetic resonance findings. There were no pathologic findings aside from minimal hepatomegaly in the liver in USG (craniocaudal length 79.6 mm) and peripheral pulmonary stenosis was detected in echocardiographic evaluation.

The patient was transferred to the department of nutrition and metabolism of the university hospital with GA II pre-diagnosis on the 22nd day after birth and was followed up for further examination and treatment regimen. Her general condition was good, and no abnormality was identified during the physical examination upon arrival at the university hospital. The laboratory findings and acylcarnitine profile are shown in Tables 1 and 2, respectively.

At the university hospital, a nasogastric tube was inserted and the patient was started on a diet of 6 mg/kg/min glucose with total parenteral nutrition containing 13% protein, 63% carbohydrate, 23% lipid, with totally 116 kcal/kg per day energy balance. After a week nutritional education was provided to the caregivers, the patient was discharged on carnitine (50 mg/kg per day), coenzyme Q10 (100 mg/d) and riboflavin (100 mg/d) supplementation with a high carbohydrate oral diet. At a follow-up after six months, ammonia levels were found to be high and sodium benzoate therapy was initiated. Meanwhile, a genetic analysis revealed, two different novel mutations in the ETF-A gene [NM_000126.3 p.L67P (c.200T>C) and Q285L (c.854A>T), compound heterozygote] and these mutations were considered to be the cause of the disease according to SIFT, PolyPhen-2, and PROVEAN databases.[6-8]

At the sixth month follow-up, although the Denver test had revealed normal findings in terms of neuromotor development before, a slight delay in neuromotor development was observed. At the age of eight months, sodium 3-hydroxybutyrate (NaHB) administration was started and gradually increased from 360 mg/kg to 1400 mg/kg by the end of the 12th month, together with the high carbohydrate diet. Diet challenge was undertaken according to the plasma acylcarnitine and ketone body levels. After the diet alignments, the patient’s neuromotor development was noted to increase significantly.

In the second year, follow-up laboratory tests identified low mean corpuscular volume (< 65 fl) and high red blood cell (5.5 × 10⁶/µL). A hemoglobin electrophoresis was performed and results confirmed the diagnosis of thalassemia minor. Following these diagnostic tests, a percutaneous endoscopic gastrostomy (PEG) tube was inserted. The patient has been closely followed with carnitine, riboflavin, coenzyme Q10, and 1600 mg/kg per day ketone treatment in addition to a high carbohydrate diet. Patient is followed with routine controls and infections are monitored and treated immediately. Although she is slightly overweight, her neuromotor development is normal for her age and she has no major health problems.

DISCUSSION
Glutaric acidemia type II is among the severe inborn errors of metabolism and it may be associated with significant morbidity and mortality, particularly in the neonatal-onset patients.[1] Neonatal-onset form patients may develop severe respiratory failure, cardiomyopathy, hypotonia, metabolic acidosis, and profound hypoglycemia soon after birth, which corresponds with short life expectancy[2].

The patient in the present case report had severe hypoglycemia on the postnatal first day, and diagnosis was achieved by the expanded newborn screening analysis. Acylcarnitines in dried blood spots were analyzed using a tandem mass spectrometry after butyl-derivatization. Urine organic acids were analyzed by gas chromatograph mass spectrometer and showed increased excretion of GA II characteristic compounds, such as adipate, suberate, glutarate, 2-hydroxyglutarate, ethylmalonate, or isovalerylglucine, which are the corresponding metabolites derived from defective acyl-CoA dehydrogenase reaction steps[9]. As a result of these findings, together with those of genetic analysis, our patient was diagnosed with GA II, neonatal-onset form without congenital anomalies.
The most important goal of newborn screening for inborn errors of metabolism is to reduce morbidity and mortality by early interventions such as dietary and pharmacologic treatments\(^1\). In recent years, expanded NBS using tandem mass spectrometry eased the detection of many inborn errors of metabolism in asymptomatic newborns. Screening for GA II, which is estimated to have a prevalence of 1/200000, is also very important given the potential for early detection and intervention such as our case. The patient in the present study was diagnosed through the use of advanced technologies and the timely application of therapies enabled the patient to reach the second year of life without major health problems.

Our patient was diagnosed with thalassemia minor in the second year of life. In thalassemia minor (Tm), hemoglobin synthesis is decreased, but individuals are generally considered healthy. However, Tm is thought to be a potential risk for cardiovascular, neurological, metabolic, and vascular complications\(^2\) and, as a result of increased iron absorption, ineffective erythropoiesis, erythroid hyperplasia, and decreased antioxidant capacity, Tm affects health expectations\(^3\). Coexistence of GA II and thalassemia minor in our patient may make her prone to infections and a decreased tolerance to complications may be expected.

Pharmacological therapy for GA II is based on the administration of L-carnitine, Coenzyme Q10, and riboflavin (vitamin B2)\(^4\). Unfortunately, response is often poor to these treatments. Although ketone therapy is still at the experimental stage, sodium 3-hydroxybutyrate (NaHB) administration has emerged as a promising form of treatment, enabling the replacement of the deficient endogenous ketone body production needed not only for energy supply, but also for the synthesis of complex cell and tissue components such as myelin in the central nervous system\(^5\). Studies have shown that NaHB treatment results in the improvement of cardiomyopathy, hypotonia, and feeding tolerance in GA II patients\(^6\).

In our patient, in addition to routine therapy, ketone supplementation was started at eight months and the dose was increased gradually from 360 mg/kg/d to 1600 mg/kg/d, which significantly increased neuromotor development in a short time. Ketone body treatment is also thought to increase resistance to infection in GA II patients\(^7-9\). Moreover a PEG tube insertion was another advantage for the patient because it allowed the family and caregivers to easily apply the planned diet and medications and prevent hypoglycemia attacks.

In conclusion, expanded NBS by tandem MS has made it possible to detect GA II in this particular patient and enabled us to make early interventions for the patient who additionally had thalassemia minor. To our knowledge the present case report is the only one reporting a patient with both GA II and thalassemia minor. Ketone body treatment should be considered to be part of routine therapy in GA II patients with existing comorbidities, such as in our case. Finally, this patient’s genetic analysis added two novel mutations of the ETF-A gene to the literature.

**ARTICLE HIGHLIGHTS**

**Case characteristics**

An episode of hypoglycemia and hypotonicity occurred on the postnatal first day, and the patient was admitted to neonatal intensive care unit.

**Clinical diagnosis**

Patient’s general condition was good. No abnormality was identified during the physical examination.

**Differential diagnosis**

Metabolic diseases were investigated with tandem mass spectrometry.

**Laboratory diagnosis**

Tandem mass spectrometry, high pressure liquid chromatography, and mass spectrometry measurements in newborn screening enabled us to diagnose the patient very early.

**Imaging diagnosis**

Cranial Doppler ultrasonography (USG) and cranial magnetic resonance findings were normal, and there were no pathologic findings aside from minimal hepatomegaly in the liver.

**Treatment**

Patient was treated with carnitine, riboflavin, Coenzyme Q10, and ketone treatment in addition to a high carbohydrate diet.

**Related reports**

Glutaric academia type II (GA II) was first described in 1976 and is estimated to have a prevalence of 1/200000 live births. There are a few case reports describing the neonatal-onset form of the disease in the literature since the life-expectancy is short. There are also some cases reports describing adult-onset forms, which are mild with the patients living until adulthood.

**Term explanation**

Tandem mass spectrometer: High pressure liquid chromatography and tandem mass spectrometry.

**Experiences and lessons**

Expanded new born screening by tandem mass spectrometry has made it possible to detect GA II in this particular patient and enabled us to make early interventions for the patient. Moreover ketone treatment seems to be advantageous in GA II patients, particularly in cases with comorbidities.

**REFERENCES**

1. Angle B, Burton BK. Risk of sudden death and acute life-threatening events in patients with glutaric acidemia type II. *Mol Genet Metab* 2008; 93: 36-39 [PMID: 17977044 DOI: 10.1016/j.ymgme.2007.09.015]

2. Yamada K, Kobayashi H, Bo R, Takahashi T, Purevsuren J, Hasegawa Y, Taketani T, Fukuda S, Okubo T, Yokota T, Watanabe M, Tsunemi T, Mizusawa H, Takuma H, Shioya A, Ishii A, Tamaoka A, Shigematsu Y, Sugie H, Yamaguchi S, Clinical, biochemical and molecular investigation of adult-onset glutaric acidemia type II: Characteristics in comparison with pediatric cases. *Brain Dev* 2016; 38: 293-301 [PMID: 26403312 DOI: 10.1016/j.braindev.2015.08.011]
3 Ersoy EO, Rama D, Unal Ö, Sivri S, Topeli A. Glutaric aciduria type 2 presenting with acute respiratory failure in an adult. Respir Med Case Rep 2015; 15: 92-94 [PMID: 26236614 DOI: 10.1016/j.rmed.2015.02.009]

4 Domizio S, Romanelli A, Brindisino P, Puglielli C, Conte E, Domizio R, Sgarrella MC, Sabatino G. Glutaric aciduria type II: a case report. Int J Immunopathol Pharmacol 2005; 18: 805-808 [PMID: 16388731 DOI: 10.1177/039463200501800425]

5 Beresford MW, Pourfarzam M, Turnbull DM, Davidson JE. So doctor, what exactly is wrong with my muscles? Glutaric aciduria type II presenting in a teenager. Neuromuscul Disord 2006; 16: 269-273 [PMID: 16527485 DOI: 10.1016/j.nmd.2006.01.001]

6 Sorting Intolerant Form Tolerant. Genome Tools. Available from: URL: http://sift-dna.org

7 Harvard University. PolyPhen-2. Available from: URL: http://genetics.bwh.harvard.edu/pph2/

8 J Craig Venter Institute. PROVEAN. Available from: URL: http://provean.jcvi.org

9 Yamaguchi S, Orii T, Suzuki Y, Maeda K, Oshima M, Hashimoto T. Newly identified forms of electron transfer flavoprotein deficiency in two patients with glutaric aciduria type II. Pediatr Res 1991; 29: 60-63 [PMID: 2000260 DOI: 10.1203/00006450-199101000-00012]

10 Graffeo L, Vitrano A, Scondotto S, Dardanoni G, Pollina Addario WS, Giambona A, Sacco M, Di Maggio A, Renda D, Taormina F, Triveri A, Attanasio M, Gliud C, Maggio A. β-Thalassemia heterozygote state detrimentally affects health expectation. Eur J Intern Med 2018; 54: 76-80 [PMID: 29934240 DOI: 10.1016/j.ejim.2018.06.009]

11 Rosa M, Pascarella A, Parenti G, Buono S, Romano A, Della Casa R, Andria G, Marino M, Riccio MP, Bravaccio C. Developmental evolution in a patient with multiple acyl-coenzymeA dehydrogenase deficiency under pharmacological treatment. Eur J Paediatr Neurol 2012; 16: 203-205 [PMID: 21868270 DOI: 10.1016/j.ejpn.2011.07.003]

12 Gautschi M, Weistamter C, Slotboom J, Nava E, Zürcher T, Nuoßer JM. Highly efficient ketone body treatment in multiple acyl-CoA dehydrogenase deficiency-related leukodystrophy. Pediatr Res 2015; 77: 91-98 [PMID: 25289702 DOI: 10.1038/pr.2014.154]

13 Van Hove JL, Grünewald S, Jaeken J, DEMAEREL PE, Declercq PE, Bourdoux P, Niezen-Koning K, Deanfield JE, Leonard JV. D,L-3-hydroxybutyrate treatment of multiple acyl-CoA dehydrogenase deficiency (MADD). Lancer 2003; 361: 1433-1435 [PMID: 12727399 DOI: 10.1016/S0140-6736(03)13105-4]

14 Van Rijt WJ, Heiner-Fokkema MR, du Marchie Sarvaas GI, Waterham HR, Blokpoel RG, van spronsen FJ, Derks TG. Favorable outcome after physiologic dose of sodium-D,L-3-hydroxybutyrate in severe MADD. Pediatrics 2014; 134: e1224-e1228 [PMID: 25246622 DOI: 10.1542/peds.2013-4254]

P- Reviewer: Anis S, Kai K  S- Editor: Wang XJ  L- Editor: Filipodia  E- Editor: Song H
